MX370481B - Combinaciones de elementos de vector de expresión, métodos novedosos de generación de células de producción y su uso para la producción recombinante de polipéptidos. - Google Patents

Combinaciones de elementos de vector de expresión, métodos novedosos de generación de células de producción y su uso para la producción recombinante de polipéptidos.

Info

Publication number
MX370481B
MX370481B MX2017012736A MX2017012736A MX370481B MX 370481 B MX370481 B MX 370481B MX 2017012736 A MX2017012736 A MX 2017012736A MX 2017012736 A MX2017012736 A MX 2017012736A MX 370481 B MX370481 B MX 370481B
Authority
MX
Mexico
Prior art keywords
vectors containing
clones
signal sequence
polya signal
productivity
Prior art date
Application number
MX2017012736A
Other languages
English (en)
Inventor
Knoetgen Hendrik
Michael Huelsmann Peter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX370481B publication Critical patent/MX370481B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

En la presente se reporta que para transfecciones transitorias el uso del promotor alfa de factor 1 de elongación humano (con el intrón A) proporciona una productividad mejorada (en organización de LC-HC-SM), el uso de la secuencia de señal poliA de hormona del crecimiento bovina proporciona una productividad mejorada en comparación con el uso de la secuencia de señal poliA de SV40, la adición de hGT a la secuencia de señal poliA de bGH resulta en una productividad aumentada en vectores que contienen el promotor hCMV y la organización de vector CL (3'-5')-HC-SM resulta en expresión mejorada. Para acumulados estables se reporta que acumulados generados con vectores que contienen el promotor a de hEF1 muestran una productividad mejorada en análisis por lotes, clones generados con los vectores que contienen el promotor hEF1a muestran un número reducido de clones poco productores, y los clones generados con vectores que contienen el promotor hEF1a muestran una mayor estabilidad de expresión de IgG. Para clones únicos se reporta que la organización del vector con la posición corriente abajo del marcador de selección (LC-HC-SM) tiene un efecto positivo sobre la productividad de clones únicos y que los clones generados con vectores que contienen la secuencia de señal poliA de bGH y hGT tienen las mayores productividades.
MX2017012736A 2011-12-22 2012-12-19 Combinaciones de elementos de vector de expresión, métodos novedosos de generación de células de producción y su uso para la producción recombinante de polipéptidos. MX370481B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11195361 2011-12-22
PCT/EP2012/076203 WO2013092743A2 (en) 2011-12-22 2012-12-19 Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides

Publications (1)

Publication Number Publication Date
MX370481B true MX370481B (es) 2019-12-16

Family

ID=47504950

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014007359A MX355624B (es) 2011-12-22 2012-12-19 Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.
MX2017012736A MX370481B (es) 2011-12-22 2012-12-19 Combinaciones de elementos de vector de expresión, métodos novedosos de generación de células de producción y su uso para la producción recombinante de polipéptidos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014007359A MX355624B (es) 2011-12-22 2012-12-19 Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.

Country Status (14)

Country Link
US (2) US20160208284A1 (es)
EP (2) EP3354660A1 (es)
JP (4) JP6096802B2 (es)
KR (4) KR102048556B1 (es)
CN (4) CN113896787A (es)
BR (1) BR112014014239B1 (es)
CA (2) CA3149402A1 (es)
ES (1) ES2930215T3 (es)
HR (1) HRP20221383T1 (es)
MX (2) MX355624B (es)
PL (1) PL2794651T3 (es)
RU (2) RU2756910C2 (es)
SG (3) SG10201900915WA (es)
WO (1) WO2013092743A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113896787A (zh) * 2011-12-22 2022-01-07 弗·哈夫曼-拉罗切有限公司 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
US11046975B2 (en) 2013-10-07 2021-06-29 Prestige Biopharma Pte. Ltd. Bicistronic expression vector for antibody expression and method for producing antibody using same
CN105255867A (zh) * 2015-10-19 2016-01-20 北京益生合生物科技有限公司 一种防止启动子在传代培养中逐渐灭活的基因序列及其应用
JP6937309B2 (ja) 2016-01-27 2021-09-22 ジャスト−エヴォテック バイオロジックス、インコーポレイテッド ハイブリッドプロモーターおよびその使用
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
JP7042263B2 (ja) 2016-10-20 2022-03-25 サンガモ セラピューティクス， インコーポレイテッド ファブリー病の治療のための方法および組成物
CA3063320A1 (en) * 2017-05-19 2018-11-22 Council Of Scientific & Industrial Research A method for producing refolded recombinant humanized ranibizumab
JP7081139B2 (ja) * 2017-12-20 2022-06-07 東ソー株式会社 新規プロモーターおよびそれを含む発現ベクター
MX2021003273A (es) * 2018-09-20 2021-07-16 Sanofi Sa Metodos y composiciones de clonacion universal basados en intrones.
EP3856910B1 (en) 2018-09-24 2024-11-20 Merck Sharp & Dohme LLC Expression vectors for eukaryotic expression systems
WO2020084034A1 (en) * 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange
CA3130546A1 (en) 2019-03-29 2020-10-08 Tilman Schlothauer Method for the generation of an fcrn expressing cell by targeted integration of multiple expression cassettes in a defined organization
KR102798616B1 (ko) 2019-12-20 2025-04-22 (주)셀트리온 목적 단백질의 고발현을 위한 인트론을 포함하는 발현 카세트 및 이의 이용
EP4265715A4 (en) * 2021-01-12 2024-11-27 JCR Pharmaceuticals Co., Ltd. Nucleic acid molecule containing incorporated gene encoding fused protein of ligand and protein having physiological activity
EP4284834A1 (en) 2021-01-29 2023-12-06 Merck Sharp & Dohme LLC Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
JP2025510135A (ja) * 2022-03-24 2025-04-14 セル・アンド・ブレイン・カンパニー・リミテッド 新規組換えベクターおよびその用途
WO2024239229A1 (zh) * 2023-05-23 2024-11-28 西安佑佰生物科技有限公司 一种增强相邻启动子转录活性的载体及其方法
KR102640929B1 (ko) 2023-06-02 2024-02-27 (주) 멥스젠 미세생체조직시스템 형성 장치

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
JP3051411B2 (ja) 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69333807T2 (de) 1992-02-06 2006-02-02 Chiron Corp., Emeryville Marker für krebs und biosynthetisches bindeprotein dafür
RU2201449C2 (ru) * 1994-10-14 2003-03-27 Сембайозис Дженетикс Инк. Слитый полипептид, способный к целенаправленному переносу к масляному телу, химерная днк-контрукция, экспрессирующая кассета
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
WO2001044463A1 (en) 1999-12-15 2001-06-21 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
EP1308517A1 (en) * 2001-10-31 2003-05-07 Aventis Pharmacueticals Products Inc. Vectors for expressing multiple transgenes
IL161988A0 (en) * 2001-11-16 2005-11-20 Corporation Idec Pharmaceutica Polycistronic expression of antibodies
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
CN100383244C (zh) * 2003-01-07 2008-04-23 西福根有限公司 用于生产重组多克隆蛋白质的方法
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CN1942483B (zh) 2004-04-13 2012-09-26 弗·哈夫曼-拉罗切有限公司 抗p型选凝素抗体
CN101001953B (zh) * 2004-06-17 2013-03-13 惠氏公司 具有三个完整转录单元的质粒和用于诱导hiv免疫反应的免疫原性组合物
WO2007045465A1 (en) * 2005-10-21 2007-04-26 F. Hoffmann-La Roche Ag Method for the recombinant expression of a polypeptide
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US20080124760A1 (en) * 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
EP2059533B1 (en) 2006-08-30 2012-11-14 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CA2672979A1 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Selection method
US7935808B2 (en) * 2007-03-30 2011-05-03 Abbott Laboratories Recombinant expression vector elements (rEVEs) for enhancing expression of recombinant proteins in host cells
EP1995309A1 (en) * 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
AU2008271658B8 (en) * 2007-06-29 2013-07-04 F. Hoffmann-La Roche Ag Promoter
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
KR101734585B1 (ko) * 2008-08-28 2017-05-11 노파르티스 아게 정지 코돈 번역초과에 의한 폴리펩티드 이소형의 세포 표면 표시
GB0903207D0 (en) * 2009-02-25 2009-04-08 Ucb Pharma Sa Method for expressing multimeric proteins
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
CN102369214B (zh) 2009-04-07 2019-04-12 罗氏格黎卡特股份公司 三价、双特异性抗体
EP2435473B1 (en) 2009-05-27 2013-10-02 F.Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
CN113896787A (zh) * 2011-12-22 2022-01-07 弗·哈夫曼-拉罗切有限公司 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途

Also Published As

Publication number Publication date
KR102229491B1 (ko) 2021-03-18
JP6096802B2 (ja) 2017-03-15
JP2017108753A (ja) 2017-06-22
EP2794651A2 (en) 2014-10-29
HK1200848A1 (en) 2015-08-14
EP3354660A1 (en) 2018-08-01
EP2794651B1 (en) 2022-09-21
WO2013092743A3 (en) 2013-10-03
KR20210031002A (ko) 2021-03-18
MX2014007359A (es) 2014-08-01
WO2013092743A2 (en) 2013-06-27
CN107119073A (zh) 2017-09-01
CN113881702B (zh) 2025-05-30
ES2930215T3 (es) 2022-12-07
CA2854249A1 (en) 2013-06-27
BR112014014239B1 (pt) 2021-10-13
CN104011075B (zh) 2017-06-06
RU2639519C2 (ru) 2017-12-21
US20160208284A1 (en) 2016-07-21
JP6417436B2 (ja) 2018-11-07
US20210024952A1 (en) 2021-01-28
JP2019030311A (ja) 2019-02-28
RU2756910C2 (ru) 2021-10-06
BR112014014239A2 (pt) 2017-12-26
KR20190132702A (ko) 2019-11-28
SG10201900915WA (en) 2019-03-28
CN113896787A (zh) 2022-01-07
PL2794651T3 (pl) 2022-12-27
KR20200032240A (ko) 2020-03-25
HRP20221383T1 (hr) 2023-01-06
KR102048556B1 (ko) 2019-11-26
RU2017140661A3 (es) 2021-08-09
CN104011075A (zh) 2014-08-27
SG10201700169PA (en) 2017-02-27
JP2020054372A (ja) 2020-04-09
JP2015500656A (ja) 2015-01-08
KR102166824B1 (ko) 2020-10-19
CN113881702A (zh) 2022-01-04
SG11201403443WA (en) 2014-07-30
CA3149402A1 (en) 2013-06-27
KR20140106585A (ko) 2014-09-03
CA2854249C (en) 2022-05-03
RU2017140661A (ru) 2019-02-12
KR102285184B1 (ko) 2021-08-03
JP7096806B2 (ja) 2022-07-06
MX355624B (es) 2018-04-25
RU2014129727A (ru) 2016-02-20

Similar Documents

Publication Publication Date Title
MX370481B (es) Combinaciones de elementos de vector de expresión, métodos novedosos de generación de células de producción y su uso para la producción recombinante de polipéptidos.
FI3536797T3 (fi) Siirtogeenin tehostettu ilmentäminen ja prosessointi
MY189314A (en) Cells for producing recombinant iduronate-2-sulfatase
UA129709C2 (uk) ПОЛІПЕПТИД З ПРОТЕАЗНОЮ АКТИВНІСТЮ IdeS
WO2016092550A3 (en) Methods of producing long acting ctp-modified polypeptides
EP4624490A3 (en) Modified fc region of antibody
RU2014148136A (ru) Композиции т-клеток с недостаточностью рецепторов т-клеток
MX2011013183A (es) Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso.
MX2009012747A (es) Produccion de proteina recombinante en celulas ebx de aves.
MX384246B (es) POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß.
MX355650B (es) Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
MY161552A (en) A polynucleotide and polypeptide sequence and methods thereof
HRP20200744T1 (hr) Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida
HRP20201442T1 (hr) Poboljšano rekombinantno izražavanje proteina korištenjem hibridnog promotora chef1
WO2007003582A3 (en) Serum-free stable transfection and production of recombinant human proteins in human cell lines
MX365947B (es) Operaciones de cosecha mejoradas para proteinas recombinadas.
JP2017524366A5 (es)
MX2014003508A (es) Vectores basados en el virus de la tristeza de los cítricos para la expresion de gen/es ajenos.
MX2015015519A (es) Regulador de papalisina.
MX392532B (es) Glicoproteinas recombinantes y sus usos.
MX2013011355A (es) Metodo de produccion de polipeptido recombinante.
MX2015013842A (es) Metodos y constructos para expresar proteinas biologicamente activas en celulas de mamifero.
EP2573169A4 (en) CORTAR-SPECIFIC HIF-2 TRANSGENE MOUSE AS AN ANIMAL MODEL FOR ARTHRITIS AND APPLICATION THEREOF
ES2597966T3 (es) Método para la producción en masa de factor VII/VIIa
SG194473A1 (en) EXPRESSION SYSTEM WITH SAR ELEMENT FROM IFNa2